This paper surveyed all the scientific articles about tirzepatide and found that research on this drug is rapidly growing, especially in the US, with a focus on how it works, its clinical results, and how studies are designed. New interest areas include weight loss, safety monitoring, and cost‑effectiveness, while long‑term safety and accessibility remain unclear.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A structured search of the Scopus database was performed using the keywords "tirzepatide" in titles or abstracts, limited to English-language original articles. A total of 446 documents were retrieved. Bibliometric analysis was conducted using VOSviewer (v1.6.19), Biblioshiny (Rstudio plugin), and CiteSpace (v6.2.R6) to visualize co-authorship, keyword co-occurrence, citation patterns, and thematic evolution. Tirzepatide publications peaked in 2024 (n = 163), with the USA leading (n = 243, 10,076 citations). Key authors included Urva, S. and Haupt, A. Three thematic clusters emerged: pharmacological mechanisms, clinical outcomes, and study design. Emerging topics included weight reduction, pharmacovigilance, and cost-effectiveness. Co-citation analysis identified four author clusters, with Frias J.P. (TLS = 13,605) most influential. Journals like Diabetes, Obesity and Metabolism dominated. Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness.